Contemporary management of patients with Type 2 diabetes.
EVALUATION OF: Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with Type 2 diabetes. Am. J. Hypertens. 23(3), 334-339 (2010). Type 2 diabetes is often accompanied by other comorbidities that similarly contribute to cardiovascular risk. New antidiabetics including glucagon-like peptide-1 agonists have demonstrated blood glucose control in patients with Type 2 diabetes with a low risk of hypoglycemia and a favorable impact on bodyweight. Evidence suggests that these agents may convey benefit in managing additional cardiovascular risks. In a recent pooled analysis of randomized controlled trial data, Okerson et al. identified a significant reduction in systolic blood pressure in patients treated with exenatide, particularly in patients with elevated systolic blood pressure. This study provides further evidence that glucagon-like peptide-1 agonists confer therapeutic benefit for managing Type 2 diabetes while also managing other cardiovascular risk factors.
University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA. carrie.mcadam-marx@pharm.utah.edu
Carrie
C
McAdam-Marx
Julia A
JA
Gaebler
Brandon K
BK
Bellows
Diana I
DI
Brixner